Unixell Biotech Achieves FDA Clearance for Revolutionary Epilepsy Cell Therapy Unixell Biotech has received FDA IND clearance for UX-GIP001, a groundbreaking cell therapy for focal epilepsy, revolutionizing treatment options.

Unixell Biotech Achieves FDA Clearance for Revolutionary Epilepsy Cell Therapy #China #Shanghai #Epilepsy #UniXell_Biotech #UX-GIP001

Revolutionary Cell Therapy Study Provides Hope for Huntington's Disease Patients A groundbreaking study published in the Journal of Clinical Investigation reveals a novel cell therapy approach for Huntington's disease, led by Dr. Yuejun Chen of UniXell Biotech.

Revolutionary Cell Therapy Study Provides Hope for Huntington's Disease Patients #China #Shanghai #Huntington's_Disease #UniXell_Biotech #Dr._Yuejun_Chen

Unixell Biotech's UX-DA001: A Breakthrough in Parkinson's Disease Therapy Unixell Biotech unveils promising results for UX-DA001, a pioneering iPSC-derived therapy for Parkinson's, showcased at MDS Congress 2025.

Unixell Biotech's UX-DA001: A Breakthrough in Parkinson's Disease Therapy #China #Shanghai #Parkinson's_Disease #UniXell_Biotech #UX-DA001

Innovative Cell Therapy Techniques Show Promise in Treating Depression A groundbreaking study demonstrates the efficacy of cell therapy in treating depression, offering new hope for patients with treatment-resistant cases. Discover the findings from UniXell Biotech.

Innovative Cell Therapy Techniques Show Promise in Treating Depression #China #Shanghai #depression_treatment #UniXell_Biotech #A10_Neurons

UniXell Biotechnology Achieves Milestone in Parkinson's Cell Therapy Trial UniXell Biotechnology has successfully dosed the first patient with UX-DA001, advancing its groundbreaking trial for a Parkinson's treatment.

UniXell Biotechnology Achieves Milestone in Parkinson's Cell Therapy Trial #China #Shanghai #Parkinson's_Disease #UniXell_Biotech #UX-DA001